Grifols (NASDAQ:GRFS) Sees Large Volume Increase – Here’s What Happened

Grifols, S.A. (NASDAQ:GRFS) saw strong trading volume on Wednesday . 1,401,980 shares traded hands during mid-day trading, an increase of 8% from the previous session’s volume of 1,298,023 shares.The stock last traded at $7.68 and had previously closed at $7.73.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley started coverage on shares of Grifols in a research report on Wednesday, February 12th. They set an “overweight” rating on the stock.

Grifols Stock Down 0.5 %

The firm’s fifty day simple moving average is $7.49 and its 200-day simple moving average is $8.15. The company has a market cap of $5.31 billion, a PE ratio of 6.60 and a beta of 0.35. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11.

Hedge Funds Weigh In On Grifols

A number of institutional investors have recently made changes to their positions in the stock. R Squared Ltd purchased a new stake in Grifols during the 4th quarter worth about $28,000. GAMMA Investing LLC boosted its stake in shares of Grifols by 44.5% during the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 1,527 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Grifols by 254.0% during the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock worth $52,000 after buying an additional 4,970 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Grifols by 354.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 6,335 shares during the last quarter. Finally, First Trust Advisors LP purchased a new position in shares of Grifols during the fourth quarter valued at approximately $75,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.